The USPTO will have an examining attorney review your application; if there are any deficiencies in your application or objections from parties affecting by your application, you'll have to address them before your logo can be trademarked.
While a great essay won't make up for poor academic preparation or other deficiencies in an application, it can mean the difference between admission and rejection.
While the sample of studies was small, these results indicate that many cluster randomized trials of cancer screening interventions have had deficiencies in the application of correct statistical procedures for the outcome analysis, and that increased adoption of appropriate methods in the early and mid-2000's may not have been sustained.
He realized that European chemistry research in the 1950s had, in contrast to research in America, great deficiencies in the application of modern physical chemistry, particularly of spectroscopic analysis methods.
A systematic review of the literature has reported that many cluster randomized cancer screening intervention trials (19 CRC only and 6 CRC plus other sites) had deficiencies in the application of correct statistical procedures for the outcome analysis which led to unjustified rejection of the null hypothesis [ 17].
The visit to Syncon was part of the agency's response to Lilly's request for reconsideration, Schuda said".VA officials are ready to assist Mr. Lilly and other veteran entrepreneurs to correct all deficiencies in their applications and become eligible for participation,'' she said.
(i) Notify the applicant of the receipt of, and of any deficiency in, the application.
Here, we aimed to optimize the optical and mechanical properties of RAFT TE for treatment of LESC deficiency in clinical application.
The funding decision is made on what is essentially a different application, which is submitted after input from the shortlisting board, potentially correcting deficiencies in the original application so these results should be interpreted with caution.
For example, Bristol-Myers Squibb may have missed crucial deficiencies in ImClone's application to the Food and Drug Administration for its colorectal cancer drug before it agreed to invest $2 billion in ImClone last fall.
